SER recommendations on the use of biological drugs in primary Sjögren's syndrome-Reference-Cited by-同舟云学术

SER recommendations on the use of biological drugs in primary Sjögren's syndrome

Published:2019-11 Issue:6 Volume:15 Page:315-326
ISSN:2173-5743
Container-title:Reumatología Clínica (English Edition)
language:en
Short-container-title:Reumatología Clínica (English Edition)

Author:

Andréu Sánchez José Luis,Fernández Castro Mónica,Díaz del Campo Fontecha Petra,Corominas Héctor,Narváez García Francisco Javier,Rosas Gómez de Salazar José,Rua-Figueroa Íñigo,Abad Hernández Miguel Ángel,Álvarez Rivas María Noelia,del Pino Montes Javier,Francisco Hernández Félix Manuel,Gantes Pedraza María Ángeles,Greco Merino Martín Gerardo,Hernández María Vanesa,Navarro Compán María Victoria,Solarte Juan Alberto Paz,Romero Bueno Fredeswinda I.,Park Hye Sang,Sivera Mascaró Francisca,Rivas María Noelia Álvarez,Montes Javier del Pino,Pedraza María Ángeles Gantes,Merino Martín Gerardo Greco,Hernández María Vanesa,Solarte Juan Alberto Paz,Bueno Fredeswinda I. Romero,Park Hye Sang,Abad Hernández Miguel Ángel,Hernández Félix Manuel Francisco,Compán María Victoria Navarro,Mascaró Fran Sivera

Funder

Spanish Rheumatology Foundation

Publisher

Elsevier BV

Reference77 articles.

1. Sjogren syndrome;Brito-Zeron;Nat Rev Dis Primers,2016

2. Primary Sjogren's syndrome: clinical phenotypes, outcome and the development of biomarkers;Goules;Immunol Res,2017

3. Autoantibodies in Sjogren's syndrome;Fayyaz;Rheum Dis Clin North Am,2016

4. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis;Qin;Ann Rheum Dis,2015

5. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients;Ramos-Casals;Medicine (Baltimore),2008